Novo Nordisk India launched Awiqli, the first once-weekly basal insulin for diabetes, reducing injections from daily to weekly. In a statement, it said that more than 101 million people in India are living with diabetes, while an additional 136 million have prediabetes.
Novo Nordisk India launched Awiqli, the first once-weekly basal insulin for diabetes, reducing injections from daily to weekly. In a statement, it said that more than 101 million people in India are living with diabetes, while an additional 136 million have prediabetes.
<iframe src="https://hindustansphere.com/embed/cluster/78ec623628e6ba8e2e4db7c631ad6f0c30c10e3e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Nordisk insulin pen price in India: How much will once-weekly Awiqli cost you? Check its variants"></iframe>
Novo Nordisk India launched Awiqli, the first once-weekly basal insulin for diabetes, reducing injections from daily to weekly. In a statement, it said that more than 101 million people in India are living with diabetes, while an additional 136 million have prediabetes.
